
TGF-β exhibits dual tumor-suppressive and tumor-promoting effects in colorectal cancer (CRC). Using patient-derived tumoroids (PDTs), we observed that early-stage tumors respond to TGF-β with tumor suppression, while advanced-stage tumors show reduced sensitivity. Notably, a tumoroid harboring a KRASQ22K mutation exhibited partial epithelial-to-mesenchymal transition (EMT), increased invasiveness, and mesenchymal gene expression.
Like
Save
Share